Roche Holdings, Ltd.

Roche Holdings, Ltd. operates in the pharmaceutical and diagnostic businesses worldwide. The pharmaceutical business consists of oncology products, which include CERA, NeoRecormon, MabThera/Rituxan, Pegasys, Herceptin, Xeloda, CellCept, and Fuzeon. The CERA and NeoRecormon products are used to treat anemia. The MabThera/Rituxan product is used for rheumatoid arthritis. The Pegasys is hepatitis C drug. The Fuzeon is a HIV fusion inhibitor. Xeloda and Herceptin are used to treat breast cancer. The CellCept is an anti AIDS drug. The diagnostic business comprises diabetes care, molecular diagnostics, and immunochemistry. The company has a collaboration agreement with Actelion, Ltd. for the development and commercialization of S1P1 receptor agonist, an immunomodulator; an agreement with Plexxikon, Inc. for the development and commercialization of cancer therapy products; and a collaboration agreement with Dako A/S to study EGFR PharmDx for use as an aid in the assessment of patients with a diagnosis of non-small cell lung cancer. Roche Holdings was founded by Fritz Hoffmann-La Roche in 1896. The company is headquartered in Basel, Switzerland.